Your browser doesn't support javascript.
loading
High intratumoural galectin-1 expression predicts adverse outcome in ALK- ALCL and CD30+ PTCL-NOS.
Holst, Johanne Marie; Ludvigsen, Maja; Hamilton-Dutoit, Stephen Jacques; Bendix, Knud; Plesner, Trine Lindhardt; Nørgaard, Peter; Møller, Michael B; Steiniche, Torben; Rabinovich, Gabriel A; d'Amore, Francesco; Pedersen, Martin Bjerregård.
Affiliation
  • Holst JM; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
  • Ludvigsen M; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Hamilton-Dutoit SJ; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
  • Bendix K; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Plesner TL; Department of Pathology, Aarhus University Hospital, Aarhus, Denmark.
  • Nørgaard P; Department of Pathology, Aarhus University Hospital, Aarhus, Denmark.
  • Møller MB; Department of Pathology, Aarhus University Hospital, Aarhus, Denmark.
  • Steiniche T; Department of Pathology, Herlev Hospital, Herlev, Denmark.
  • Rabinovich GA; Department of Pathology, Odense University Hospital, Odense, Denmark.
  • d'Amore F; Department of Pathology, Aarhus University Hospital, Aarhus, Denmark.
  • Pedersen MB; Institute of Biology and Experimental Medicine, National Council of Scientific and Technical Investigations, Buenos Aires, Argentina.
Hematol Oncol ; 38(1): 59-66, 2020 Feb.
Article in En | MEDLINE | ID: mdl-31834627
Galectin-1 (Gal-1) has been associated with adverse prognosis in several cancers including lymphoma entities with CD30 expression. However, Gal-1 expression has not been systematically assessed in peripheral T-cell lymphomas (PTCL). Specimens from 169 nodal PTCL were assessed for intratumoural Gal-1 expression by immunohistochemistry. Overall survival (OS) in groups exhibiting high and low Gal-1 expression was compared in the cohort and in a subset analysis of CD30-positive PTCL only. Gal-1 expression was also correlated with biomarkers of the tumour microenvironment. No significant difference in OS based on Gal-1 expression was observed in the entire PTCL cohort. However, in the CD30-positive cohort, patients with high Gal-1 levels had significantly poorer outcome (5 years OS 10%, 95% confidence interval CI, 1-36) than their low Gal-1 counterparts (5 years OS 48%, 95% CI, 30-64, P = .021). In univariate analyses age 60 or younger, non-elevated lactate dehydrogenase (LDH), and performance score less than 2 correlated with superior survival but high Gal-1 expression significantly predicted adverse outcome at both univariate (HR 2.5, 95% CI, 1.1-5.7, P = .026) and multivariate levels (HR 3.2, 95% CI, 1.2-8.5, P = .017). Tumours with high Gal-1 had few cytotoxic T cells in the tumour microenvironment. High intratumoural Gal-1 expression before therapeutic intervention correlates with adverse outcome in nodal CD30+ , ALK- PTCL patients.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Lymphoma, T-Cell, Peripheral / Lymphoma, Large-Cell, Anaplastic / Ki-1 Antigen / Galectin 1 / Anaplastic Lymphoma Kinase Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Hematol Oncol Year: 2020 Type: Article Affiliation country: Denmark

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Lymphoma, T-Cell, Peripheral / Lymphoma, Large-Cell, Anaplastic / Ki-1 Antigen / Galectin 1 / Anaplastic Lymphoma Kinase Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Hematol Oncol Year: 2020 Type: Article Affiliation country: Denmark